Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ardelyx, Inc. - Common Stock (NQ:ARDX)

6.320 -0.060 (-0.94%)
Streaming Delayed Price Updated: 2:35 PM EDT, Aug 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ardelyx, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Nvidia, Boeing, Ardelyx, Crocs, Tesla: Why These 5 Stocks Are On Investors' Radars Today
 
Via Benzinga
Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of RxSight, Inc. (NASDAQ: RXST) rose sharply during Monday’s session after the company issued preliminary FY23 and FY24 revenue guidance above estimates. Also, Needham maintained a Buy rating on... 
Via Benzinga
What's Going On With Ardelyx Stock?
Ardelyx, Inc. (NASDAQ: ARDX) shares are trading higher Monday after the company provided a strategic business update. 
Via Benzinga
The Latest Analyst Ratings for Ardelyx
 
Via Benzinga
Why Ardelyx Stock Soared Today
Ardelyx delivered a strong quarter thanks to solid demand for its first FDA-approved product. Here's what investors need to know. 
Via The Motley Fool
Ardelyx Provides Update on Growing Commercial Momentum and 2024 Strategic Priorities
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx to Provide Company Update on IBSRELA® and Host a KOL Discussion on the IBS-C Landscape on Monday, January 8
Live event and webcast scheduled for 7:00 p.m. ET / 4:00 p.m. PT 
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx, Inc. Reports Employment Inducement Grants
From Ardelyx, Inc.
Via GlobeNewswire
Positive News For Skin Health: Aldeyra Therapeutics' ADX-629 Achieves Key Milestones in Atopic Dermatitis Study
Aldeyra Therapeutics Inc (NASDAQ: ALDX) released topline results from a Phase 2 clinical trial of ADX-629, an investigational RASP modulator, in  
Via Benzinga
Patient Demand Drives Ardelyx's Constipation Drug Success Amid IBS-C Treatment Gap, Says Analyst
Raymond James initiated coverage of Ardelyx Inc (NASDAQ: ARDX), noting the company's two early-stage launches underway for the same molecule with differentiated pricing: 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
3 Short-Squeeze Stocks Ready for a Year-End Rally
These are a few companies that have seen considerable gains this year that still have a large percentage of short interest. 
Via InvestorPlace
Ardelyx, Inc. Reports Employment Inducement Grants
From Ardelyx, Inc.
Via GlobeNewswire
7 Penny Stocks You’ll Regret Not Buying Soon: November 2023
Unlock robust upside potential by wagering on these top penny stocks to buy in a volatile market at this time. 
Via InvestorPlace
Ardelyx to Participate at the Piper Sandler 35th Annual Healthcare Conference
From Ardelyx, Inc.
Via GlobeNewswire
XPHOZAH® (tenapanor) Granted Orphan Drug Designation by U.S. FDA for the Treatment of Pediatric Hyperphosphatemia
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Announces Departure of Board Member
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx to Participate at the Jefferies London Healthcare Conference
From Ardelyx, Inc.
Via GlobeNewswire
5 OTC Stocks With The Potential To Explode In 2024
Investors who are ready to dive into the OTC pool have more options than ever, both with the number of stocks to choose from and available investing platforms. 
Via Benzinga
Ardelyx Announces XPHOZAH® (tenapanor) Now Available in the United States
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Shares Positive Data from Studies of XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor, at ASN Kidney Week 2023
From Ardelyx, Inc.
Via GlobeNewswire
Arista Networks, JinkoSolar, Repligen, Shutterstock And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones falling more than 50 points on Tuesday. Here are some major stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Ardelyx Reports Third Quarter 2023 Financial Results and Updates 2023 U.S. IBSRELA® Net Sales Revenue Guidance
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx, Inc. Reports Employment Inducement Grants
From Ardelyx, Inc.
Via GlobeNewswire
3 Penny Stocks to Buy and Hold for the Next 10 Years
These three penny stocks are the ones to buy and hold through the market conditions and the years to come for returns. 
Via InvestorPlace
Ardelyx Shares Positive Data on Symptom Response During Treatment With IBSRELA® (tenapanor) for IBS-C and hosts IBS-C Product Theater at ACG 2023
From Ardelyx, Inc.
Via GlobeNewswire
Tesla, Nokia And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures traded lower this morning on Thursday. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Why Ardelyx Stock Popped Today
Ardelyx finally received the long-awaited FDA approval for its chronic kidney disease drug. 
Via The Motley Fool
Ardelyx to Report Third Quarter 2023 Financial Results on October 31, 2023
Conference call scheduled for 8:00 a.m. Eastern Time 
From Ardelyx, Inc.
Via GlobeNewswire
Crude Oil Rises Sharply; Ardelyx Shares Spike Higher
U.S. stocks traded lower toward the end of trading, with the S&P 500 falling more than 1% on Wednesday. The Dow traded down 0.70% to 33,760.26 while the NASDAQ fell 1.45% to 13,338.71. The S&P 500 also... 
Via Benzinga
Topics Stocks
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback